Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Single-Turnover Activation of Arp2/3 Complex by Dip1 May Balance Nucleation of Linear versus Branched Actin Filaments.

Balzer CJ, Wagner AR, Helgeson LA, Nolen BJ.

Curr Biol. 2019 Oct 7;29(19):3331-3338.e7. doi: 10.1016/j.cub.2019.08.023. Epub 2019 Sep 26.

PMID:
31564494
2.

Dip1 Co-opts Features of Branching Nucleation to Create Linear Actin Filaments that Activate WASP-Bound Arp2/3 Complex.

Balzer CJ, Wagner AR, Helgeson LA, Nolen BJ.

Curr Biol. 2018 Dec 3;28(23):3886-3891.e4. doi: 10.1016/j.cub.2018.10.045. Epub 2018 Nov 21.

3.

Structure of the nucleation-promoting factor SPIN90 bound to the actin filament nucleator Arp2/3 complex.

Luan Q, Liu SL, Helgeson LA, Nolen BJ.

EMBO J. 2018 Nov 15;37(22). pii: e100005. doi: 10.15252/embj.2018100005. Epub 2018 Oct 15.

4.

Identification of Wiskott-Aldrich syndrome protein (WASP) binding sites on the branched actin filament nucleator Arp2/3 complex.

Luan Q, Zelter A, MacCoss MJ, Davis TN, Nolen BJ.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1409-E1418. doi: 10.1073/pnas.1716622115. Epub 2018 Jan 31.

5.

Identification of an ATP-controlled allosteric switch that controls actin filament nucleation by Arp2/3 complex.

Rodnick-Smith M, Liu SL, Balzer CJ, Luan Q, Nolen BJ.

Nat Commun. 2016 Jul 15;7:12226. doi: 10.1038/ncomms12226.

6.

Role and structural mechanism of WASP-triggered conformational changes in branched actin filament nucleation by Arp2/3 complex.

Rodnick-Smith M, Luan Q, Liu SL, Nolen BJ.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3834-43. doi: 10.1073/pnas.1517798113. Epub 2016 Jun 20.

7.

Team training to establish a safety culture in dialysis access surgery.

Davidson I, Widmer MK, Nolen B, Ross J, Slakey DP.

Contrib Nephrol. 2015;184:97-106. doi: 10.1159/000365826. Epub 2015 Feb 9.

PMID:
25676295
8.

Urinary protein biomarkers in the early detection of lung cancer.

Nolen BM, Lomakin A, Marrangoni A, Velikokhatnaya L, Prosser D, Lokshin AE.

Cancer Prev Res (Phila). 2015 Feb;8(2):111-9. doi: 10.1158/1940-6207.CAPR-14-0210. Epub 2014 Nov 21.

9.

Interactions with actin monomers, actin filaments, and Arp2/3 complex define the roles of WASP family proteins and cortactin in coordinately regulating branched actin networks.

Helgeson LA, Prendergast JG, Wagner AR, Rodnick-Smith M, Nolen BJ.

J Biol Chem. 2014 Oct 17;289(42):28856-69. doi: 10.1074/jbc.M114.587527. Epub 2014 Aug 26.

10.

Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma.

Nolen BM, Breen EC, Bream JH, Jenkins FJ, Kingsley LA, Rinaldo CR, Lokshin AE.

PLoS One. 2014 Jun 12;9(6):e99144. doi: 10.1371/journal.pone.0099144. eCollection 2014.

11.

Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.

Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A, Lokshin AE.

PLoS One. 2014 Apr 18;9(4):e94928. doi: 10.1371/journal.pone.0094928. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117876. Huang, Ying [added].

12.

Dip1 defines a class of Arp2/3 complex activators that function without preformed actin filaments.

Wagner AR, Luan Q, Liu SL, Nolen BJ.

Curr Biol. 2013 Oct 21;23(20):1990-8. doi: 10.1016/j.cub.2013.08.029. Epub 2013 Oct 10.

13.

Mechanism of synergistic activation of Arp2/3 complex by cortactin and N-WASP.

Helgeson LA, Nolen BJ.

Elife. 2013 Sep 3;2:e00884. doi: 10.7554/eLife.00884.

14.

Structural basis for regulation of Arp2/3 complex by GMF.

Luan Q, Nolen BJ.

Nat Struct Mol Biol. 2013 Sep;20(9):1062-8. doi: 10.1038/nsmb.2628. Epub 2013 Jul 28.

15.

An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors.

Nolen BM, Orlichenko LS, Marrangoni A, Velikokhatnaya L, Prosser D, Grizzle WE, Ho K, Jenkins FJ, Bovbjerg DH, Lokshin AE.

PLoS One. 2013 May 28;8(5):e63368. doi: 10.1371/journal.pone.0063368. Print 2013.

16.

Small molecules CK-666 and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating conformational change.

Hetrick B, Han MS, Helgeson LA, Nolen BJ.

Chem Biol. 2013 May 23;20(5):701-12. doi: 10.1016/j.chembiol.2013.03.019. Epub 2013 Apr 25.

17.

Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Nolen BM, Lokshin AE.

Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6. Review.

18.

Circulating prolactin levels and risk of epithelial ovarian cancer.

Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, Berrino F, Hallmans G, Idahl A, Krogh V, Lukanova A, Marrangoni A, Muti P, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A.

Cancer Causes Control. 2013 Apr;24(4):741-8. doi: 10.1007/s10552-013-0156-6. Epub 2013 Feb 3.

19.

Virtual reality: emerging role of simulation training in vascular access.

Davidson IJ, Lok C, Dolmatch B, Gallieni M, Nolen B, Pittiruti M, Ross J, Slakey D.

Semin Nephrol. 2012 Nov;32(6):572-81. doi: 10.1016/j.semnephrol.2012.10.009.

PMID:
23217338
20.

Insertions within the actin core of actin-related protein 3 (Arp3) modulate branching nucleation by Arp2/3 complex.

Liu SL, May JR, Helgeson LA, Nolen BJ.

J Biol Chem. 2013 Jan 4;288(1):487-97. doi: 10.1074/jbc.M112.406744. Epub 2012 Nov 12.

21.

Structural characterization and computer-aided optimization of a small-molecule inhibitor of the Arp2/3 complex, a key regulator of the actin cytoskeleton.

Baggett AW, Cournia Z, Han MS, Patargias G, Glass AC, Liu SY, Nolen BJ.

ChemMedChem. 2012 Jul;7(7):1286-94. doi: 10.1002/cmdc.201200104. Epub 2012 May 23.

22.

Multianalyte assay systems in the differential diagnosis of ovarian cancer.

Nolen BM, Lokshin AE.

Expert Opin Med Diagn. 2012 Mar;6(2):131-138.

23.

Serum biomarker profiles as diagnostic tools in lung cancer.

Nolen BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, Bigbee WL, Weissfeld JL, Wilson DO, Dacic S, Siegfried JM, Lokshin AE.

Cancer Biomark. 2011-2012;10(1):3-12. doi: 10.3233/CBM-2012-0229.

24.

Protein biomarkers of ovarian cancer: the forest and the trees.

Nolen BM, Lokshin AE.

Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135. Review.

25.

Factors associated with inflammation markers, a cross-sectional analysis.

Clendenen TV, Koenig KL, Arslan AA, Lukanova A, Berrino F, Gu Y, Hallmans G, Idahl A, Krogh V, Lokshin AE, Lundin E, Muti P, Marrangoni A, Nolen BM, Ohlson N, Shore RE, Sieri S, Zeleniuch-Jacquotte A.

Cytokine. 2011 Dec;56(3):769-78. doi: 10.1016/j.cyto.2011.09.013. Epub 2011 Oct 19.

26.

-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Nolen BM, Lokshin AE.

Int J Biol Markers. 2011 Jul-Sep;26(3):141-52. doi: 10.5301/JBM.2011.8613. Epub 2011 Sep 21. Review.

27.

Structural and biochemical characterization of two binding sites for nucleation-promoting factor WASp-VCA on Arp2/3 complex.

Ti SC, Jurgenson CT, Nolen BJ, Pollard TD.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):E463-71. doi: 10.1073/pnas.1100125108. Epub 2011 Jun 15.

28.

Circulating inflammation markers and risk of epithelial ovarian cancer.

Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, Lokshin AE, Idahl A, Ohlson N, Hallmans G, Krogh V, Sieri S, Muti P, Marrangoni A, Nolen BM, Liu M, Shore RE, Arslan AA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):799-810. doi: 10.1158/1055-9965.EPI-10-1180. Epub 2011 Apr 5.

29.

Mechanism of a concentration-dependent switch between activation and inhibition of Arp2/3 complex by coronin.

Liu SL, Needham KM, May JR, Nolen BJ.

J Biol Chem. 2011 May 13;286(19):17039-46. doi: 10.1074/jbc.M111.219964. Epub 2011 Mar 21.

30.

Serum biomarker panels for the detection of pancreatic cancer.

Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE.

Clin Cancer Res. 2011 Feb 15;17(4):805-16. doi: 10.1158/1078-0432.CCR-10-0248.

31.

Simulation training for vascular access interventions.

Davidson IJ, Yoo MC, Biasucci DG, Browne P, Dees C, Dolmatch B, Gallieni M, La Greca A, Korndorffer JR, Nolen B, O'Rear S, Peden E, Pittiruti M, Reed G, Scott D, Slakey D.

J Vasc Access. 2010 Jul-Sep;11(3):181-90. Review.

PMID:
21240863
32.

The expansion and advancement of cancer biomarkers.

Nolen B.

Cancer Biomark. 2011-2012;10(2):61-2. doi: 10.3233/CBM-2012-0233. No abstract available.

PMID:
22430132
33.

Temporal reliability of cytokines and growth factors in EDTA plasma.

Clendenen TV, Arslan AA, Lokshin AE, Idahl A, Hallmans G, Koenig KL, Marrangoni AM, Nolen BM, Ohlson N, Zeleniuch-Jacquotte A, Lundin E.

BMC Res Notes. 2010 Nov 13;3:302. doi: 10.1186/1756-0500-3-302.

34.

Development of a multimarker assay for early detection of ovarian cancer.

Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE.

J Clin Oncol. 2010 May 1;28(13):2159-66. doi: 10.1200/JCO.2008.19.2484. Epub 2010 Apr 5.

35.

Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A.

Gynecol Oncol. 2010 Jun;117(3):440-5. doi: 10.1016/j.ygyno.2010.02.005. Epub 2010 Mar 24.

36.

Targeting CCL11 in the treatment of ovarian cancer.

Nolen BM, Lokshin AE.

Expert Opin Ther Targets. 2010 Feb;14(2):157-67. doi: 10.1517/14728220903512983. Review.

PMID:
20055715
37.

Screening for ovarian cancer: old tools, new lessons.

Nolen BM, Lokshin AE.

Cancer Biomark. 2010-2011;8(4-5):177-86. doi: 10.3233/CBM-2011-0210. Review.

PMID:
22045352
38.

Characterization of two classes of small molecule inhibitors of Arp2/3 complex.

Nolen BJ, Tomasevic N, Russell A, Pierce DW, Jia Z, McCormick CD, Hartman J, Sakowicz R, Pollard TD.

Nature. 2009 Aug 20;460(7258):1031-4. doi: 10.1038/nature08231. Epub 2009 Aug 2.

39.

Biological significance of prolactin in gynecologic cancers.

Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, Mor G, Maxwell LG, Herberman RB, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.

Cancer Res. 2009 Jun 15;69(12):5226-33. doi: 10.1158/0008-5472.CAN-08-4652. Epub 2009 Jun 2.

40.

Role of eotaxin-1 signaling in ovarian cancer.

Levina V, Nolen BM, Marrangoni AM, Cheng P, Marks JR, Szczepanski MJ, Szajnik ME, Gorelik E, Lokshin AE.

Clin Cancer Res. 2009 Apr 15;15(8):2647-56. doi: 10.1158/1078-0432.CCR-08-2024. Epub 2009 Apr 7.

41.

Aberrant tumor-associated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay.

Nolen B, Winans M, Marrangoni A, Lokshin A.

J Immunol Methods. 2009 May 31;344(2):116-20. doi: 10.1016/j.jim.2009.03.017. Epub 2009 Apr 5.

42.

Nucleotide- and activator-dependent structural and dynamic changes of arp2/3 complex monitored by hydrogen/deuterium exchange and mass spectrometry.

Zencheck WD, Xiao H, Nolen BJ, Angeletti RH, Pollard TD, Almo SC.

J Mol Biol. 2009 Jul 17;390(3):414-27. doi: 10.1016/j.jmb.2009.03.028. Epub 2009 Mar 17.

43.

Autoantibodies for cancer detection: still cause for excitement?

Nolen BM, Lokshin AE.

Cancer Biomark. 2010;6(5-6):229-45. doi: 10.3233/CBM-2009-0137. Review.

PMID:
20938084
44.

Incompatibility with formin Cdc12p prevents human profilin from substituting for fission yeast profilin: insights from crystal structures of fission yeast profilin.

Ezezika OC, Younger NS, Lu J, Kaiser DA, Corbin ZA, Nolen BJ, Kovar DR, Pollard TD.

J Biol Chem. 2009 Jan 23;284(4):2088-97. doi: 10.1074/jbc.M807073200. Epub 2008 Nov 20.

45.

A serum based analysis of ovarian epithelial tumorigenesis.

Nolen B, Marrangoni A, Velikokhatnaya L, Prosser D, Winans M, Gorelik E, Lokshin A.

Gynecol Oncol. 2009 Jan;112(1):47-54. doi: 10.1016/j.ygyno.2008.09.043. Epub 2008 Nov 12.

46.

Chemotherapeutic drugs and human tumor cells cytokine network.

Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E.

Int J Cancer. 2008 Nov 1;123(9):2031-40. doi: 10.1002/ijc.23732.

47.

Structure and biochemical properties of fission yeast Arp2/3 complex lacking the Arp2 subunit.

Nolen BJ, Pollard TD.

J Biol Chem. 2008 Sep 26;283(39):26490-8. doi: 10.1074/jbc.M802607200. Epub 2008 Jul 18.

48.

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.

Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE.

Breast Cancer Res. 2008;10(3):R45. doi: 10.1186/bcr2096. Epub 2008 May 12.

49.

Nucleotide-mediated conformational changes of monomeric actin and Arp3 studied by molecular dynamics simulations.

Dalhaimer P, Pollard TD, Nolen BJ.

J Mol Biol. 2008 Feb 8;376(1):166-83. Epub 2007 Nov 28.

50.

Supplemental Content

Support Center